Literature DB >> 26837843

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Z Chen1,2, J E Cortes3, J L Jorgensen1, W Wang1, C C Yin1, M J You1, E Jabbour2, H M Kantarjian2, L J Medeiros1, S Hu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26837843      PMCID： PMC5115880          DOI： 10.1038/leu.2016.6

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Authors:  Alice Fabarius; Armin Leitner; Andreas Hochhaus; Martin C Müller; Benjamin Hanfstein; Claudia Haferlach; Gudrun Göhring; Brigitte Schlegelberger; Martine Jotterand; Andreas Reiter; Susanne Jung-Munkwitz; Ulrike Proetel; Juliana Schwaab; Wolf-Karsten Hofmann; Jörg Schubert; Hermann Einsele; Anthony D Ho; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Michael Lauseker; Markus Pfirrmann; Joerg Hasford; Susanne Saussele; Rüdiger Hehlmann
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

2.  Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.

Authors:  Alfonso Zaccaria; Nicoletta Testoni; Anna Maria Valenti; Simona Luatti; Michela Tonelli; Giulia Marzocchi; Raffaella Cipriani; Carmen Baldazzi; Barbara Giannini; Monica Stacchini; Carla Gamberini; Fausto Castagnetti; Gianantonio Rosti; Annalisa Azzena; Francesco Cavazzini; Anna Maria Cianciulli; Alessia Dalsass; Emilio Donti; Emilia Giugliano; Alessandro Gozzetti; Maria Grazia Grimoldi; Sonia Ronconi; Alessandra Santoro; Francesco Spedicato; Lucia Zanatta; Michele Baccarani
Journal:  Cancer Genet Cytogenet       Date:  2010-06

3.  How I treat CML blast crisis.

Authors:  Rüdiger Hehlmann
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

4.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Authors:  L Kalmanti; S Saussele; M Lauseker; M C Müller; C T Dietz; L Heinrich; B Hanfstein; U Proetel; A Fabarius; S W Krause; S Rinaldetti; J Dengler; C Falge; E Oppliger-Leibundgut; A Burchert; A Neubauer; L Kanz; F Stegelmann; M Pfreundschuh; K Spiekermann; C Scheid; M Pfirrmann; A Hochhaus; J Hasford; R Hehlmann
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

5.  Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Authors:  Simona Luatti; Fausto Castagnetti; Giulia Marzocchi; Carmen Baldazzi; Gabriele Gugliotta; Ilaria Iacobucci; Giorgina Specchia; Lucia Zanatta; Giovanna Rege-Cambrin; Rege Cambrin; Marco Mancini; Elisabetta Abruzzese; Alfonso Zaccaria; Maria Grazia Grimoldi; Alessandro Gozzetti; Gaia Ameli; Maria Adele Capucci; Giandomenico Palka; Paolo Bernasconi; Francesca Palandri; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani; Nicoletta Testoni
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

Review 6.  The Biology of CML blast crisis.

Authors:  Jerald P Radich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

7.  Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.

Authors:  Wei Wang; Jorge E Cortes; Pei Lin; Michael W Beaty; Di Ai; Hesham M Amin; Timothy J McDonnell; Chi Young Ok; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2015-08-04       Impact factor: 22.113

Review 8.  How I treat newly diagnosed chronic myeloid leukemia in 2015.

Authors:  Carlo Gambacorti-Passerini; Rocco Piazza
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

9.  Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.

Authors:  Wiltrud Haaß; Helga Kleiner; Christel Weiß; Claudia Haferlach; Brigitte Schlegelberger; Martin C Müller; Rüdiger Hehlmann; Wolf-Karsten Hofmann; Alice Fabarius; Wolfgang Seifarth
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

10.  On the Power of Additional and Complex Chromosomal Aberrations in CML.

Authors:  Karin M Greulich-Bode; Barbara Heinze
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236
View more
  14 in total

1.  Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.

Authors:  Daniel W Thomson; Nur Hezrin Shahrin; Paul P S Wang; Carol Wadham; Naranie Shanmuganathan; Hamish S Scott; Marcel E Dinger; Timothy P Hughes; Andreas W Schreiber; Susan Branford
Journal:  Leukemia       Date:  2020-02-19       Impact factor: 11.528

2.  Research in the heart of hematology: chronic myeloid leukemia 2017.

Authors:  Rüdiger Hehlmann
Journal:  Haematologica       Date:  2017-03       Impact factor: 9.941

3.  Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.

Authors:  Zimu Gong; L Jeffrey Medeiros; Jorge E Cortes; Zi Chen; Lan Zheng; Yan Li; Shi Bai; Pei Lin; Roberto N Miranda; Jeffrey L Jorgensen; Timothy J McDonnell; Wei Wang; Hagop M Kantarjian; Shimin Hu
Journal:  Blood Adv       Date:  2017-12-08

4.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

5.  B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.

Authors:  Alisha D Ware; Laura Wake; Patrick Brown; Jonathan A Webster; B Douglas Smith; Amy S Duffield
Journal:  AJSP Rev Rep       Date:  2019 Sep-Oct

6.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Wei Wang; Jorge E Cortes; Guilin Tang; Joseph D Khoury; Sa Wang; Carlos E Bueso-Ramos; Joseph A DiGiuseppe; Zi Chen; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2016-03-22       Impact factor: 22.113

7.  Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.

Authors:  W Wang; Z Chen; Z Hu; C C Yin; S Li; S Bai; C E Bueso-Ramos; L J Medeiros; S Hu
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

8.  Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Authors:  Z Chen; L J Medeiros; H M Kantajian; L Zheng; Z Gong; K P Patel; H Xiong; W Wang; J E Cortes; S Hu
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

9.  [Clinical significance of cytogenetic monitoring in chronic myeloid leukemia].

Authors:  C Y Pan; N Xu; B L He; R Cao; L B Liao; C X Yin; Y Q Lan; Z Y Lu; J X Huang; J Sun; R Feng; Q F Liu; X L Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-02-14

10.  Cytogenetic alterations in CML: not all created equal.

Authors:  Zimu Gong; Wei Wang; Shimin Hu
Journal:  Oncotarget       Date:  2018-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.